Blair William & Co. IL Lowers Stock Holdings in Twist Bioscience Corporation $TWST

Blair William & Co. IL reduced its stake in Twist Bioscience Corporation (NASDAQ:TWST) by 3.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 59,721 shares of the company’s stock after selling 2,245 shares during the quarter. Blair William & Co. IL owned 0.10% of Twist Bioscience worth $2,197,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of TWST. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Twist Bioscience by 186.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company’s stock valued at $95,883,000 after purchasing an additional 1,588,587 shares during the last quarter. EdgePoint Investment Group Inc. purchased a new position in shares of Twist Bioscience in the 1st quarter valued at approximately $43,705,000. Nuveen LLC purchased a new position in shares of Twist Bioscience in the 1st quarter valued at approximately $31,960,000. ARK Investment Management LLC grew its stake in shares of Twist Bioscience by 11.5% in the 1st quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company’s stock valued at $245,045,000 after purchasing an additional 645,730 shares during the last quarter. Finally, Jones Financial Companies Lllp purchased a new position in shares of Twist Bioscience in the 1st quarter valued at approximately $9,492,000.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on TWST. Cowen restated a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 4th. Evercore ISI decreased their price target on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 7th. Barclays decreased their price target on Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a research note on Thursday, October 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday, October 8th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $30.55 on Wednesday. The stock has a fifty day moving average price of $27.69 and a 200 day moving average price of $32.44. The stock has a market cap of $1.84 billion, a PE ratio of -21.07 and a beta of 2.38. Twist Bioscience Corporation has a 1 year low of $24.07 and a 1 year high of $55.33. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%.The company had revenue of $96.06 million during the quarter, compared to analysts’ expectations of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Emily M. Leproust sold 31,348 shares of the business’s stock in a transaction on Monday, October 6th. The stock was sold at an average price of $32.19, for a total value of $1,009,092.12. Following the completion of the transaction, the chief executive officer directly owned 601,212 shares of the company’s stock, valued at $19,353,014.28. The trade was a 4.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Dennis Cho sold 3,876 shares of Twist Bioscience stock in a transaction on Monday, October 6th. The shares were sold at an average price of $32.19, for a total value of $124,768.44. Following the completion of the sale, the insider directly owned 98,710 shares of the company’s stock, valued at approximately $3,177,474.90. This represents a 3.78% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 64,368 shares of company stock valued at $2,036,204. Company insiders own 3.01% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.